What is the impact of process intensification in mAb manufacturing?

Process intensification in mAb manufacturing refers to strategies that increase productivity by achieving higher cell densities, higher titers, and shorter process timelines—often using high-density cell banks, N-1 perfusion, intensified fed-batch, automation, and high-throughput downstream technologies.

Why is downstream intensification critical when upstream titers increase?

Higher upstream titers significantly increase the quantity of drug substance entering downstream operations. Without downstream intensification, purification, buffer preparation, and polishing steps can become bottlenecks, limiting overall throughput and increasing cost per gram.

How does integrated intensification improve manufacturing economics?

When upstream and downstream intensification are designed together, productivity gains compound across the process. Integrated platforms have demonstrated >150% increases in throughput, ~30–50% reductions in cost per gram, and meaningful reductions in footprint and labor demand, without compromising product quality*.

Does intensified processing affect mAb product quality?

When properly designed and controlled, intensified processes can maintain consistent product quality across scales. Integrated automation, real-time PAT, and high-capacity purification technologies help ensure comparable purity, aggregation, and charge variant profiles from development through manufacturing.

Is process intensification scalable for commercial manufacturing?

Yes. Integrated intensification strategies have been successfully demonstrated from bench scale through pilot and manufacturing-relevant scales (e.g., 500 L), showing strong comparability in cell growth, titer, yield, and product quality.

Life in the Lab

From Titer to Throughput: How Integrated Process Intensification Is Reshaping mAb Manufacturing

Instagram
This field is for validation purposes and should be left unchanged.
First Name
Last Name
Email*
Company
Select your country/region*
Pick a category*
*
- I would like to receive information about content, events, products, services and promotions from Thermo Fisher Scientific and its affiliates. I agree for the Thermo Fisher Scientific group (thermofisher.com/legalentities) to contact me by email and/or telephone to inform me of events, products, services and/or promotions offered in connection with the brands Thermo Scientific™, Applied Biosystems™, Invitrogen™, Gibco™, Ion Torrent ™, Unity Lab Services™, Fisher Scientifc™. I can withdraw my consent and unsubscribe at any time by emailing reply@thermofisher.com By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Thermo Fisher Scientific Policy (thermofisher.com/privacypolicy).

Get news and research reviews on the topic of your choice, right in your inbox.

Subscribe Now

LinkedIn
This field is for validation purposes and should be left unchanged.
First Name
Last Name
Email*
Company
Select your country/region*
Pick a category*
*
- I would like to receive information about content, events, products, services and promotions from Thermo Fisher Scientific and its affiliates. I agree for the Thermo Fisher Scientific group (thermofisher.com/legalentities) to contact me by email and/or telephone to inform me of events, products, services and/or promotions offered in connection with the brands Thermo Scientific™, Applied Biosystems™, Invitrogen™, Gibco™, Ion Torrent ™, Unity Lab Services™, Fisher Scientifc™. I can withdraw my consent and unsubscribe at any time by emailing reply@thermofisher.com By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Thermo Fisher Scientific Policy (thermofisher.com/privacypolicy).

From Titer to Throughput: How Integrated Process Intensification...

Breaking Boundaries: Immortalizing Hybridoma-Derived Antibodies ...

Parkin Antibodies: Challenges, Detection Strategies and Advances...

From Discovery to Clinic: Streamlining the RUO-to-GMP Transition...

How can bioprocessing professionals evolve their manufacturing f...

Scale Up or Scale Out? Choosing an Adherent Cell Culture Platfor...

Lipid Nanoparticles for In Vivo Gene Editing

Scaling mAb Manufacturing: Turning Lab Success into Commercial P...

12 Women Scientists Who Shaped STEM History

Thermo Fisher Scientific Partners with AIM Biotech on Developmen...